v3.3.1.900
Income Taxes (Details 1) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2016
 [1]
Sep. 27, 2015
 [2]
Jun. 28, 2015
 [3]
Mar. 29, 2015
 [4]
Dec. 28, 2014
 [5]
Sep. 28, 2014
 [6]
Jun. 29, 2014
 [7]
Mar. 30, 2014
 [8]
Jan. 03, 2016
Dec. 28, 2014
Dec. 29, 2013
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract                      
U.S.                 $ 8,179 $ 8,001 $ 4,261
International                 11,017 12,562 11,210
Earnings before provision for taxes on income $ 3,758 $ 4,122 $ 5,741 $ 5,575 $ 2,703 $ 6,810 $ 5,626 $ 5,424 $ 19,196 [9] $ 20,563 [10] $ 15,471 [11]
Tax Rates:                      
U.S. statutory rate                 35.00% 35.00% 35.00%
International operations excluding Ireland                 (6.70%) (7.00%) (10.60%)
Ireland and Puerto Rico operations(1) [12]                 (8.70%) (6.90%) (9.00%)
Research and orphan drug tax credits                 (0.20%) (0.30%) (0.80%)
U.S. state and local                 0.40% 1.00% 0.40%
U.S. manufacturing deduction                 (0.60%) (0.60%) (0.80%)
U.S. tax on international income                 0.20% 1.40% 1.70%
U.S. tax benefit on asset/business disposals                 0.00% (1.90%) (5.10%)
All other                 0.30% (0.10%) (0.20%)
Effective tax rate                 19.70% 20.60% 10.60%
[1] The fourth quarter of 2015 includes a restructuring charge of $415 million after-tax ($590 million before-tax), $156 million after-tax ($214 million before-tax) from impairment of in-process research and development and Synthes integration costs of $59 million after-tax ($83 million before-tax). Additionally, the fourth quarter of 2015 includes the gain on the Cordis divestiture.
[2] The third quarter of 2015 includes net litigation expense of $348 million after-tax ($409 million before-tax).
[3] The second quarter of 2015 includes net litigation expense of $23 million after-tax ($134 million before-tax).
[4] The first quarter of 2015 includes a net litigation gain of $253 million after-tax ($402 million before-tax) and $122 million after-tax ($139 million before-tax) for costs associated with the DePuy ASRTM Hip program.
[5] The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[6] The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[7] The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[8] The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
[9] The Medical Devices segment includes a restructuring charge of $590 million, an intangible asset write-down of $346 million related to Acclarent, Synthes integration costs of $196 million and $148 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136 million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation settlement agreement with Guidant for $600 million. The Medical Devices Segment includes a gain of $1.3 billion from the divestiture of the Cordis business. The Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA® and a positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment includes a gain of $229 million from the divestiture of SPLENDA® brand.
[10] Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. The Pharmaceutical segment includes an additional year of the Branded Prescription Drug Fee of $220 million and a positive adjustment of $0.1 billion to previous reserve estimates.
[11] Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
[12] The Company has subsidiaries operating in Puerto Rico under various tax incentives.